参考文献/References:
[1] Mouchtouris N,Chalouhi N,Chitale A,et al. Management of cerebral cavernous malformations:from diagnosis to treatment[J]. Scientific World Journal,2015,2015:1-8.
[2] Nannucci S, Pescini F, Poggesi A, et al. Familial cerebral cavernous malformation:report of a further Italian family[J]. Neurological Sciences, 2009, 30(2):143-147.
[3] Chan A C, Li D Y, Berg M J, et al. Recent insights into cerebral cavernous malformations:animal models of CCM and the human phenotype[J]. FEBS Journal, 2010, 277(5):1076-1083.
[4] Campbell P G, Jabbour P, Yadla S, et al. Emerging clinical imaging techniques for cerebral cavernous malformations:a systematic review[J]. Neurosurgical Focus, 2010, 29(3):1-15.
[5] Lehnhardt F G, Von Smekal U, Rückriem B, et al. Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation[J]. Archives of Neurology, 2005, 62(4):653-658.
[6] 蔡青,王首杰,冯达云,等.以颅神经损害症状首发的脑干海绵状血管瘤的外科治疗[J].临床神经外科杂志,2017,14(3):194-196, 201.
[7] 陈彤,郭亮.颅内海绵状血管瘤的影像特点及治疗分析[J].影像诊断与介入放射学,2016,25(3):230-235.
[8] 张超超,孙玉学,李沛文,等.椎管内海绵状血管瘤的临床分析[J].中国现代医学杂志,2018,28(6):122-124.
[9] Flemming K D, Link M J, Christianson T J, et al. Use of antithrombotic agents in patients with intracerebral cavernous malformations[J]. Journal of Neurosurgery, 2013, 118(1):43-46.
[10] Schneble H M, Soumare A, Herve D A, et al. Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations[J]. Stroke, 2012, 43(12):3196-3199.
[11] Erdur H, Scheitz J F, Tuetuencue S, et al. Safety of thrombolysis in patients with acute ischemic stroke and cerebral cavernous malformations[J]. Stroke, 2014, 45(6):1846.
[12] 徐清霖.海绵状瘤的自然病程:一个家族性脑海绵状血管瘤病例汇报及文献回顾[D].杭州:浙江大学,2014.
[13] Marques I R, Antunes F, Ferreira N A. Familial cerebral cavernous malformation:Report of a novel KRIT1 mutation in a Portuguese family[J]. Seizure - European Journal of Epilepsy, 2017, 53(1):72-74.
[14] Gunel M, Awad IA, Anson J,et al. Mapping a gene causing cerebral cavernous malformation to 7ql 1. 2-q21[J]. Proc Natl Acad Sci,1995,92(14):6620-6624.
[15] Serebriiskii I, Estojak J, Sonoda G, et al. Association of Krev-1/rapla with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22[J]. Oncogene, 1997, 15(9):1043-1049.
[16] Liquori CL,Berg MJ, Siegel AM, et al Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations[J]. Am J Hum Genet, 73(6):1459-1464.
[17] Chen DH, Lipe HP, Qin Z, et al. Cerebral cavernous malformatin:novel mutation in a Chinese family and evidence for heterogeneity[J]. J Neurol Sci, 2002, 196(1):91-96.